18106-97-3

Basic information

• Product Name: 1,3,5-Triazine-2,4-diamine, 6-(2-pyrazinyl)- (9CI)
• Synonyms: 1,3,5-Triazine-2,4-diamine, 6-(2-pyrazinyl)- (9CI);6-(2-Pyrazinyl)-1,3,5-triazine-2,4-diamine;6-(Pyrazin-2-yl)-1,3,5-triazine-2,4-diamine;ENT-51408
• CAS NO: 18106-97-3
• Molecular Formula: C7H7 N7
• Molecular Weight: 0
• Mol File: 18106-97-3.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 571.1°Cat760mmHg
• Flash Point: 334°C
• Appearance: /
• Density: 1.508g/cm³
• Vapor Pressure: 4.7E-13mmHg at 25°C
• Refractive Index: 1.724
• CAS DataBase Reference: 1,3,5-Triazine-2,4-diamine, 6-(2-pyrazinyl)- (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 1,3,5-Triazine-2,4-diamine, 6-(2-pyrazinyl)- (9CI)(18106-97-3)
• EPA Substance Registry System: 1,3,5-Triazine-2,4-diamine, 6-(2-pyrazinyl)- (9CI)(18106-97-3)

Safety Data

• Hazardous Substances Data: 18106-97-3(Hazardous Substances Data)

Usage

General Description

1,3,5-Triazine-2,4-diamine, 6-(2-pyrazinyl)- (9CI) is a chemical compound that belongs to the class of triazine derivatives. It is also known as Pyrazinamide and has the molecular formula C5H5N5. Pyrazinamide is a synthetic antibiotic used in combination with other drugs to treat tuberculosis. It works by inhibiting the growth of the bacteria that cause tuberculosis, specifically by blocking the synthesis of the bacterial cell wall. Pyrazinamide is typically used in combination with other antibiotics as a first-line treatment for tuberculosis, and it is also used to prevent the spread of the disease in some cases.

InChI:InChI=1/C7H7N7/c8-6-12-5(13-7(9)14-6)4-3-10-1-2-11-4/h1-3H,(H4,8,9,12,13,14)

Upstream product

• 19847-12-2 2-pyrazine carbonitrile 
• 127099-85-8 dicyandiamide 
• 127099-85-8 N-Cyanoguanidine 

Relevant articles and documents

A copper(II) complex of 6-(pyrazin-2-yl)-1,3,5-triazine-2,4-diamine and L-serinate: synthesis, crystal structure, DNA-binding and molecular docking studies

A water-soluble Cu(II) complex, [Cu(pzta)(L-Ser)(ClO4)]·1.5H2O (pzta?=?6-(pyrazin-2-yl)-1,3,5-triazine-2,4-diamine; L-Ser?=?L-serinate), was synthesized and characterized by analytical and spectral techniques. In addition, the molecular structure of the complex was confirmed by single-crystal X-ray diffraction, revealing that the central Cu(II) atom was located in a six-coordinate distorted octahedral geometry. Multi-spectroscopic methods, viscosity measurements and thermal denaturation experiments revealed that the complex binds to DNA with apparent binding constant of 2.93?×?103?M?1 through a groove binding mode. The positive values of ΔH and ΔS obtained from isothermal titration calorimetry experiments indicated that hydrophobic interactions play an important role in the formation of the complex–DNA adduct. Molecular docking studies were carried out to better understand the binding mode of the complex with DNA.

Triazine angiogenesis inhibitors

Compounds having Formula I STR1 or pharmaceutically acceptable salts or prodrugs thereof, are useful for treating pathological states which arise from or are exacerbated by angiogenesis. The invention also relates to pharmaceutical compositions comprising these compounds and to methods of inhibiting anglogenesis in a mammal.